Cusparine

Cusparine

SCHEMBL952682

COc1cc(CCc2ccc3c(c2)OCO3)nc2ccccc12

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.53
HTR2C P28335 4/20 0.53
HTR2B P41595 4/20 0.53
ADRA1D P25100 2/20 0.49
ADRA1A P35348 2/20 0.49
ADRB1 P08588 1/20 0.49
HTR1A P08908 1/20 0.49
ADRA2A P08913 1/20 0.49
DRD2 P14416 1/20 0.49
ADRA2B P18089 1/20 0.49
ADRA2C P18825 1/20 0.49
DRD1 P21728 1/20 0.49
DRD4 P21917 1/20 0.49
SLC6A2 P23975 1/20 0.49
HTR1D P28221 1/20 0.49
SLC6A4 P31645 1/20 0.49
HTR7 P34969 1/20 0.49
HRH1 P35367 1/20 0.49
OPRM1 P35372 1/20 0.49
DRD3 P35462 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4658526 0.81 MAPT (0.60) MEN1KMT2ALMNAPDE10AHPGD
Graveolinine SCHEMBL25286396 0.78 KDM4E (0.66) MAPK1MEN1KMT2ALMNAHSD17B10
Graveolinine SCHEMBL29411843 0.78 KDM4E (0.66) MAPK1MEN1KMT2ALMNAHSD17B10
SCHEMBL29642745 0.77 HTR2A (0.58) HTR2AHTR2CHTR2BADRA1DADRA1A
SCHEMBL951425 0.76 ALDH1A1 (0.55) MEN1KMT2ALMNAHPGDALDH1A1
SCHEMBL2334699 0.74 LMNA (0.59) LMNAPDE10AHPGDALDH1A1KDM4E
Chimanine A SCHEMBL8588818 0.74 HPGD (0.59) LMNAPDE10AHPGDALDH1A1KDM4E
SCHEMBL8604814 0.72 CALM1 (0.70) HTR2AHTR2CHTR2BADRA1DADRA1A
SCHEMBL31587740 0.72 LMNA (0.56) MEN1KMT2ALMNACYP1A2CYP2D6
SCHEMBL8290938 0.71 LMNA (0.58) LMNAPDE10AHPGDALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540073-B2 Heterogeneous hydrogen-catalyst solid fuel reaction mixture and reactor BRILLIANT LIGHT POWER, INC. (US) 2026-02-03 US disclosed
WO-2025080590-A1 CO-CRYSTALLIZATION OF ACTIVES WITH SACCHARIDE-BASED MOLECULAR FRAMEWORKS SCIENTIFIC HORIZONS CONSULTING LLC (US) 2025-04-17 WO disclosed
US-20230045778-A9 HETEROGENEOUS HYDROGEN-CATALYST SOLID FUEL REACTION MIXTURE AND REACTOR BRILLIANT LIGHT POWER, INC. (US) 2023-02-09 US disclosed
US-20200299130-A1 HETEROGENEOUS HYDROGEN-CATALYST REACTOR BRILLIANT LIGHT POWER, INC. (US) 2020-09-24 US disclosed
US-10656126-B2 Pre-analysis treatment method for sample containing plurality of components with greatly different concentrations AISTI SCIENCE CO., LTD. (JP) 2020-05-19 US disclosed
US-10059872-B2 Corrosion inhibitor compositions for acidizing treatments LONZA INC. (US) 2018-08-28 US disclosed
US-20180209945-A1 PRE-ANALYSIS TREATMENT METHOD FOR SAMPLE CONTAINING PLURALITY OF COMPONENTS WITH GREATLY DIFFERENT CONCENTRATIONS AISTI SCIENCE CO., LTD. (JP) 2018-07-26 US disclosed
CN-107850581-A The analysis preprocess method of sample containing the dramatically different Multiple components of concentration 株式会社爱思迪科学 2018-03-27 CN disclosed
EP-3237573-A1 CORROSION INHIBITOR COMPOSITIONS FOR ACIDIZING TREATMENTS Lonza Inc. (US) 2017-11-01 EP disclosed
CN-107207954-A Corrosion inhibitor composition for acidification 伦萨公司 2017-09-26 CN disclosed
EP-0606380-A1 2-SUBSTITUTED QUINOLINES FOR TREATING LEISHMANIOSES INSTITUT FRANCAIS DE RECHERCHE SCIENTIFIQUE POUR LE DEVELOPPEMENT EN COOPERATION (ORSTOM) (FR) 1994-07-20 EP disclosed
US-5298220-A Forming a coating of a solution containing anioic and cationic dyes and water insoluble organonitrogen compound, drying SHIN-ETSU CHEMICAL CO., LTD. (JP) 1994-03-29 US disclosed
WO-1993007125-A1 2-SUBSTITUTED QUINOLINES FOR TREATING LEISHMANIOSES INSTITUT FRANÇAIS DE RECHERCHE SCIENTIFIQUE POUR LE DEVELOPPEMENT EN COOPERATION (ORSTOM) (FR) 1993-04-15 WO disclosed
US-5196164-A During addition polymerization, wall coating of anionic dye and cationic dye and organonitrogen compound SHIN-ETSU CHEMICAL CO., LTD. (JP) 1993-03-23 US disclosed
CN-1040206-A Prevent to form the method for polymer scale formation SHINETSU CHEMICAL CO (JP) 1990-03-07 CN disclosed
EP-0355575-A2 Method of preventing polymer scale formation Shin-Etsu Chemical Co., Ltd. (JP) 1990-02-28 EP disclosed
EP-0172427-B1 PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER Shin-Etsu Chemical Co., Ltd. (JP) 1989-07-05 EP disclosed
US-4758639-A Process for production of vinyl polymer SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-19 US disclosed
US-4757124-A Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-12 US disclosed
EP-0172427-A2 Process for production of vinyl chloride polymer Shin-Etsu Chemical Co., Ltd. (JP) 1986-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540073-B2 Heterogeneous hydrogen-catalyst solid fuel reaction mixture and reactor SCO2, SOD1, HAO2 HTR2A 3002/4885HTR2C 2381/4885HTR2B 1577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.